Modeling Primary Tumor Dynamics of Human-to-Mouse Xenografted Non-Small Cell Lung Cancer in Response to Administration of Bevacizumab and Pemetrexed-Cisplatin

International audienceSituation: Bevacizumab is an anti-angiogenic drug commonly administered contaminantly with chemotherapeutic drugs for advanced non- squamous non-small cell lung cancer (NSCLC). Bevacizumab administration transiently enhances chemotherapeutic drug delivery, resulting in increased efficacy of chemotherapeutic drugs.Objective: This analysis attempts to characterize tumor growth dynamics as measured by uorescence in response to concurrent vs. sequential administration of pemetrexed-cisplatin and bevacizumab in NSCLC tumor carrying mice.Methods:Experiment: Data comes from previous experiment where 77 mice were randomized into 5 treatment groups:i) control (saline, N=15),ii) beva then pemetrexed-cisplatan after 3 daysiii) beva then pemetrexed-cisplatan after 8 days iv) concomitant beva + pemetrexed-cisplatanv) pemetrexed cisplatin aloneStatistical Analysis: Tumor size was evaluated by uorescence and the resulting data were analyzed using the stochastic approximation expectation maximization algorithm implemented in Monolix 2018 R1. Standard model diagnostics were completed using various R packages as well as other components of the Monolix Suite